FPI-2107
- Generic Name
- FPI-2107
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
Phase 1
Recruiting
- Conditions
- Advanced Solid TumorNon-small Cell Lung CancerMetastatic Colorectal CarcinomaHead and Neck Squamous Cell CarcinomaPancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2023-11-27
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Fusion Pharmaceuticals Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT06147037
- Locations
- 🇺🇸
Hoag Hospital, Irvine, California, United States
🇺🇸UCLA Medical Center, Santa Monica, California, United States
🇺🇸Stanford Hospital and Clinics, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath